PetMed Express (NASDAQ:PETS) is scheduled to be issuing its quarterly earnings data on Monday, January 22nd. Analysts expect the company to announce earnings of $0.31 per share for the quarter.

PetMed Express (NASDAQ:PETS) last announced its quarterly earnings results on Monday, October 23rd. The company reported $0.43 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.13. PetMed Express had a net margin of 11.58% and a return on equity of 31.46%. The firm had revenue of $66.70 million for the quarter, compared to analyst estimates of $63.41 million. During the same period last year, the business earned $0.24 EPS. PetMed Express’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, analysts expect PetMed Express to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Shares of PetMed Express (NASDAQ PETS) opened at $53.24 on Friday. PetMed Express has a one year low of $19.21 and a one year high of $53.90. The company has a market cap of $1,100.00, a price-to-earnings ratio of 35.73, a P/E/G ratio of 3.02 and a beta of 1.12.

In other PetMed Express news, Director Ronald J. Korn sold 1,000 shares of the firm’s stock in a transaction on Friday, October 27th. The shares were sold at an average price of $35.57, for a total transaction of $35,570.00. Following the transaction, the director now directly owns 73,833 shares of the company’s stock, valued at approximately $2,626,239.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Menderes Akdag sold 30,000 shares of the firm’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $51.00, for a total transaction of $1,530,000.00. Following the transaction, the chief executive officer now directly owns 490,000 shares in the company, valued at $24,990,000. The disclosure for this sale can be found here. Insiders have sold a total of 51,000 shares of company stock worth $2,453,170 over the last three months. 4.00% of the stock is currently owned by insiders.

PETS has been the topic of several research analyst reports. Zacks Investment Research lowered shares of PetMed Express from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 25th. BidaskClub upgraded shares of PetMed Express from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 9th. Northcoast Research set a $58.00 price target on shares of PetMed Express and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. ValuEngine lowered shares of PetMed Express from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. Finally, Noble Financial reiterated a “hold” rating on shares of PetMed Express in a research note on Friday, October 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. PetMed Express has an average rating of “Hold” and a consensus price target of $42.80.

TRADEMARK VIOLATION NOTICE: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/01/20/petmed-express-pets-to-release-earnings-on-monday.html.

PetMed Express Company Profile

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Earnings History for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.